Impact of OKT3 treatment for steroid resistant rejection of renal allografts: the long-term outcome at a single center.
Inui
M
M
Department of Urology, Tokyo Women's Medical University, Japan.
Tanabe
K
K
Ishikawa
N
N
Tokumoto
T
T
Harano
M
M
Otsubo
S
S
Suzuki
K
K
Goya
N
N
Yagisawa
T
T
Nakazawa
H
H
Fuchinoue
S
S
Toma
H
H
D000206:Actuarial Analysis; D000208:Acute Disease; D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000188:drug therapy* / Q000453:epidemiology; D006085:Graft Survival; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology / Q000401:mortality / Q000502:physiology*; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
D000961:Antilymphocyte Serum; D006146:Guanidines; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D003404:Creatinine; C037258:gusperimus; D008775:Methylprednisolone